Protocol Ledger

NCT05442060 · Phase II · RECRUITING

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT05442060 sponsored by OBI Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-27 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05442060
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05442060
Protocol FieldVerified Registry Value
NCT IdentifierNCT05442060
Consolidated Lead SponsorOBI Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2022-07-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05442060
Hospital Research SiteLocationSite Profile
Taipei Veterans General HospitalTaipei, TaiwanOpen Hospital Dossier ->
Linkou Chang Gung Memorial HospitalTaoyuan, TaiwanOpen Hospital Dossier ->
Tri-Service General HospitalTaipei, TaiwanOpen Hospital Dossier ->
National Taiwan University HospitalTaipei, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI